Amgen, Inc. Dissolves Its Partnership With AstraZeneca In Developing Brodalumab

new_bfn_logo

 

Amgen, Inc. Dissolves Its Partnership With AstraZeneca In Developing Brodalumab


Amgen ended the agreement after it was revealed that the drug causes suicidal tendencies in patients

Amgen, Inc. (NASDAQ:AMGN) has announced that it has ended its partnership with AstraZeneca plc (ADR) (NYSE:AZN) on developing the treatment for Psoriasis and Psoriatic arthritis. Company cited safety concerns, as being the reason for dissolving the partnership with AstraZeneca.

Amgen and AstraZeneca were developing Brodalumab, a drug, which is expected to be used to treat moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. The Phase 3 trials of the drug provided positive results, after which both the companies decided that they are likely to continue with the required regulatory procedure.

(Published by Henry Williams, Picture: businessfinancenews.com)

Continued on:
businessfinancenews.com.

:: See also the Bloomberg coverage:
Amgen Ends Drug Pact With AstraZeneca After Signs of Suicide

Advertisements